Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Discussioni nella community
- Sankyo WKN 887064
Hallo liebes Parqet-Team, mir ist aufgefallen, dass die o.g. Sankyo Aktie im falschen Sektor/Branche eingruppiert wurde. Das Unternehmen vertreibt weltweit Glücksspielautomaten und wird hier als…
StevieTi II in Schnack
1 1 - (âś…)falsche Dividenden-Anzeige bei Aktien
falsche Dividenden-Anzeige u.A. bei Sony 46% vermutlich ist hier was falsch.
MW Mario Watanabe IV in Schnack
0 10
Notizie Vai al feed delle notizie
Sam Chun Dang Pharm shares surge after weight-loss pill deal with Daiichi Sankyo
Sam Chun Dang Pharm announced a joint development and commercialization agreement with Daiichi Sankyo for its oral weight-loss pill, triggering a more than 75% share rally this month and lifting chairman Yoon Dae-in into billionaire status. The company’s S-Pass technology converts injectables into pills and has attracted bullish analyst coverage; SCD is also pursuing a potentially $2 billion deal with Takeda for a long-acting injectable using its microsphere platform. SCD reported revenue growth and a 76% rise in net income year‑over‑year for the first nine months of 2025, supporting investor optimism. » Altro su forbes.com
Daiichi Sankyo launches phase‑3 study of ENHERTU with Pembrolizumab as first‑line treatment for HER2‑overexpressing NSCLC
Daiichi Sankyo and AstraZeneca have treated the first patient in the global phase‑3 DESTINY‑Lung06 study of ENHERTU in combination with Pembrolizumab as first‑line therapy for inoperable, locally advanced or metastatic HER2‑overexpressing NSCLC. The randomized trial is expected to enroll about 686 patients; the primary endpoint is progression‑free survival, with overall survival as an important secondary endpoint. The aim is to determine whether ENHERTU can replace platinum‑based chemotherapy in standard first‑line therapy and improve outcomes, as no HER2‑targeted first‑line drugs are currently approved for this patient group. » Altro su de.investing.com
FDA grants Daiichi Sankyo and Merck breakthrough therapy designation for Raludotatug Deruxtecan
The FDA has designated Raludotatug Deruxtecan from Daiichi Sankyo and Merck as a Breakthrough Therapy for the treatment of adult patients with platinum-resistant, CDH6-expressing ovarian, primary peritoneal, or fallopian tube cancer. The decision is based on data from a Phase 1 study and the ongoing Phase 2/3 study REJOICE-Ovarian01, whose Phase 3 portion has objective response rate and progression-free survival as primary endpoints. This is the first BTD for Raludotatug Deruxtecan and the second BTD since the collaboration between the two companies began. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2026, Sankyo ha già distribuito 0,24 € di dividendi. L'ultimo pagamento è avvenuto a giugno.
Dati finanziari
Nell'ultimo trimestre, Sankyo ha registrato ricavi pari a 265,9 Mln € e un utile netto di 69,62 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 265,9Â Mln | 2,12% |
| Utile lordo | 157,21Â Mln | 6,48% |
| Utile netto | 69,62Â Mln | 6,76% |
| EBITDA | 99,27Â Mln | 6,16% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 2,47 Mld € |
Numero di azioni | 197,51Â Mln |
Massimo/minimo a 52 settimane | 15,97 € - 8,77 € |
Rendimento da dividendo | 3,73% |
Dividendi TTM | 0,49 € |
Prossimo dividendo | 0,29 € |
Beta | 0,21 |
Rapporto P/E | 11,21 |
Rapporto PEG | -0,44 |
Rapporto P/B | 1,64 |
Rapporto P/S | 2,69 |
Profilo aziendale
Sankyo Co., Ltd. produce e vende macchine da gioco e sistemi di alimentazione delle sfere in Giappone. L'azienda opera attraverso i segmenti Pachinko Machines Business, Pachislot Machines Business, Ball Bearing Supply Systems Business e Other Businesses. Il segmento Pachinko Machines Business produce e vende macchine pachinko, calibri per macchine, e vende anche parti correlate. Il segmento Pachinko Machines Business produce e vende macchine pachislot e vende parti correlate. Il segmento Ball Bearing Supply Systems Business produce e vende alimentatori di sfere per pachinko e pachislot, apparecchiature per sistemi a tessera e attrezzature e periferiche per sale giochi. Il segmento Other Businesses si occupa di affitto e vendita di immobili e di vendita di parti stampate generiche. L'azienda offre inoltre servizi di contenuti mobili e gestisce un club di golf. L'azienda vende i suoi prodotti con i marchi SANKYO e Bisty. Sankyo Co., Ltd. è stata costituita nel 1960 e ha sede a Tokyo, in Giappone.
| Nome | Sankyo |
| CEO | Toshio Ogura |
| Sede centrale | Tokyo,
ty Giappone |
| Sito web | |
| Settore | SanitĂ |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 19/05/2000 |
| Dipendenti | 895 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Japan Exchange Group | 6417.T |
Pnk | SKXJF |
Frankfurt | SOK.F |
DĂĽsseldorf | SOK.DU |
MĂĽnchen | SOK.MU |